Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Company to receive $8mil+ from Ferring
From 10Q:
"Under the terms of the Distribution Agreement, Ferring is obligated to make an initial payment to the Company of $5,000,000 upon satisfaction of certain closing conditions, including an agreement from all current manufacturers of the Licensed Product that upon a material supply default by the Company, Ferring can assume a direct purchase relationship with such manufacturers. The Closing under the Distribution Agreement will not occur prior to January 14, 2019 without consent of the Company and Ferring. Ferring is obligated to make a second payment to the Company of $3,000,000 provided that the Company is successful in obtaining a five (5) day label enhancement from the FDA for the current incubation period for the Licensed Product at least three (3) years prior to the expiration of the term of the license for the Licensed Product and provided further that Ferring has not previously exercised its right to terminate the Distribution Agreement for convenience. In addition, under the terms of a separate Supply Agreement, attached as an exhibit to the Distribution Agreement, Ferring is obligated to pay the Company a specified supply price for each Licensed Product purchased by Ferring for distribution.
The Distribution Agreement has an initial term expiring on December 31, 2025 and at the end of the initial term it may be terminated by the Company if Ferring fails to generate specified minimum revenues to the Company from the sale of the Licensed Product during the final two years of the initial term. Provided that no such termination occurs at the end of the initial term, thereafter the term of the Distribution Agreement shall automatically be renewed for successive three (3) years terms unless terminated by mutual consent. The Distribution Agreement is subject to termination upon a material breach by either party, or by Ferring for convenience. In addition, if the closing under the Distribution Agreement does not occur within seventy five (75) days, a non-breaching party may elect to terminate the Distribution Agreement."
MEDFORD, Mass., Nov. 13, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), developers of the INVOcell intravaginal culture (IVC) system, and Ferring Pharmaceuticals, a specialty biopharmaceutical group committed to helping people around the world build families and live better lives, announced today that the companies have entered into an exclusive U.S. commercialization rights agreement for INVOcell. Ferring will be responsible for all U.S. commercial activities for INVOcell. INVO Bioscience will be responsible for manufacturing and supplying INVOcell to Ferring for commercial sales and to obtain a five (5) day label enhancement from the FDA for the current incubation period for the product. INVO Bioscience also retains certain limited rights to establish INVO clinics that exclusively commercialize INVO cycles and will retain commercialization rights outside the U.S.
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity.
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity.
More
The agreement is expected to close in January 2019, subject to customary closing conditions.
"We are pleased to have reached this agreement with Ferring to commercialize INVOcell in the U.S.," said Katie Karloff, Chief Executive Officer of INVO Bioscience. "Ferring has commercial strength and market presence within the pharmaceutical fertility market and understands the unique opportunity that INVOcell provides to revolutionize fertility treatment. Our joint mission at INVO Bioscience and Ferring is to increase access to care and expand fertility treatment across the U.S., and with Ferring we've found a natural partner to accomplish this goal."
"As a leader in reproductive medicine, Ferring understands that women seeking to start or expand a family want options that suit their individual circumstances," said Paul Navarre, CEO, Ferring Pharmaceuticals (US). "With this agreement, Ferring aims to make INVOcell, a novel technology used in the treatment of infertility, widely available as an option for women and their healthcare providers."
INVOcell is a novel fertility treatment that uses a woman's own body as a natural incubator for the incubation of eggs and sperm during fertilization and early embryo development. In 2015, INVOcell received US Food & Drug Administration clearance. INVOcell is the first intravaginal culture (IVC) device and is a small polystyrene capsule used for egg fertilization and embryo development using vaginal incubation. In clinical studies supporting the FDA clearance, INVOcell has shown results comparable to traditional assisted reproductive techniques.
"In my practice, an increasing number of women and couples are choosing INVOcell with favorable results," said Amber R. Cooper MD, MSCI, FACOG, Medical and IVF Practice Director of Vios Fertility Institute St. Louis, MO. "There is a growing consensus around the need for personalized medicine in reproductive health. That Ferring and INVO Bioscience are moving to make INVOcell an available option for infertility patients across the country is very welcome news."
In the United States, statistics show that over 1.4 million women may benefit from advanced fertility treatment. However, only approximately 130,000 people begin such treatment.i
Additional details pertaining to the agreement will be filed by INVO Bioscience with the SEC.
About INVO Bioscience
INVO Bioscience is a medical device company focused on creating simplified treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development. Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com.
For Safety and Efficacy information:
https://invobioscience.com/wp-content/uploads/2018/11/P-008_INVO-IFU-Nov-2018.pdf
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward- looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact
Kathleen Karloff, CEO
978-878-9505 ext. 504
kkarloff@invobio.com
i Fertility Dynamics, an independent data analytics, research and strategic advisory firm based in Washington, DC; data on file
They are on CNN!! Hurry up and get in.
https://www.cnn.com/videos/health/2018/10/31/fertility-ivf-same-sex-couple-carried-one-baby-mxp-vpx.hln
Get certification for your medical device globally. Medical device registration in India.
Positive NEWS from $IVOB today!
https://www.prnewswire.com/news-releases/invo-bioscience-announces-two-poster-presentations-at-the-2018-american-society-for-reproductive-medicine-asrm-congress--expo-300733382.html
INVO Bioscience Announces Two Poster Presentations at the 2018 American Society for Reproductive Medicine (ASRM) Congress & Expo
Among the findings, after 3 dIUI cycles, an Intravaginal culture (INVOcell) cycle appears to be a more cost-effective option for lesbian couples. $IVOB
Intravaginal culture (INVOcell) offers a significant increase in pregnancy rates compared with intrauterine insemination (IUI).
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity.
NEWS PROVIDED BY
INVO Bioscience, Inc.
08:31 ET
SHARE THIS ARTICLE
MEDFORD, Mass., Oct. 18, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who was granted FDA clearance for the first Intravaginal Culture System, today announced that two posters were presented at the 74th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) this past week in Denver, Colorado.
"ASRM was once again an incredible event for INVO Bioscience and our INVOcell device and procedure," commented Katie Karloff, CEO of INVO Bioscience. "INVOcell was highlighted in two poster presentations outlining the cost benefits of INVOcell's intravaginal culture system. The first, presented by Julia Butler, evaluated whether intravaginal culture is a more economical treatment for lesbian couples. The study found that when considering the all-in cost of treatment, that after 3 dIUI cycles (donor sperm with intrauterine insemination), an INVOcell cycle appears to be a more cost-effective option for lesbian couples. The second, presented by Ryan Miller, is a retrospective study aimed to assess the efficacy of the INVOcell intravaginal culture device with fresh transfers compared with intrauterine insemination (IUI) cycles at the Piedmont Reproductive Endocrinology Group, or PREG, where both are Clinical Embryologists and Lab Managers. The study concluded that the INVOcell intravaginal culture offers a significant increase in pregnancy rates compared with IUI and offers a novel treatment that gives patients an option between a simple IUI and a full IVF cycle. These studies affirm our mission to expand fertility treatment across the globe with a goal to lower the cost and increase availability of care."
Details of the poster presentations can be found on the INVO Bioscience website at https://invobioscience.com/resources/.
Is intravaginal culture a more economical treatment for lesbian couples?
J. Butler MS, M. Darmer BS, J. Payne MD, T. McCoy MD, E. Tarnawa MD
Piedmont Reproductive Endocrinology Group, Greenville, SC
Intravaginal embryo culture: More than just a novelty?
Ryan Miller, Travis McCoy, Edward Tarnawa, John Payne
Piedmont Reproductive Endocrinology Group, Greenville, SC
Clemson University, Clemson, SC
Additional highlights from ASRM
INVO Bioscience hosted several strategic meetings with industry leaders both from within the United States as well as internationally and assembled a KOL gathering of 30 current INVOcell adopters to discuss an array of topics, including the latest advancements in clinical management and research, and shared ideas on best practices for the INVOcell device.
INVO Bioscience's booth and participation added a critical addition to Scientific Congress & Expo by educating attendees on the novel device and procedure that provides a more natural, safe, effective and economical fertility treatment. This engagement lead to INVO Bioscience making over 200 key new contacts during the duration of the event.
Ms. Karloff concluded, "I couldn't be more pleased with the reception that we received at this year's event. It is gratifying to meet with many of our existing physicians that are utilizing INVOcell and are achieving tremendous results. Likewise, it was exciting to share the opportunity that INVOcell provides to potential new users that are looking for ways to bridge the treatment gap between providing an effective solution that can be accessible for an expanding patient population and decreased cost of care."
About INVOcell
The INVOcell device and procedure is a disruptive new technology and a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. With INVO Bioscience's mission to increase access to care and expand fertility treatment and patient care across the globe, they were a perfect addition for ASRM.
INVOcell™ key features & benefits:
Provides a more natural incubation environment.
Offers an affordable treatment, which may reduce the risk of wrong embryo transfers.
Uses mild stimulation, which may reduce the risk of ovarian hyper-stimulation.
Increases geographic accessibility (and access to care) to more patients with equivalent safety and efficacy compared to traditional IVF.
Provides psychological benefits and promotes increased involvement by couples.
Simpler procedure - decreases overall costs to physician and decreases patients costs by ~ 50% compared to IVF procedure rates.
Cost per actual pregnancy may be less than multiple IUI attempts.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504
kkarloff@invobio.com
SOURCE INVO Bioscience, Inc.
Related Links
http://invobioscience.com/
Also from this source
14 AUG, 2018, 16:05 ET
INVO Bioscience Reports Record Second Quarter 2018 Financial...
Explore
More news releases in similar topics
All Summer Health & Safety News Releases
Health
Medical Pharmaceuticals
General Business
People & Culture
You just read:
INVO Bioscience Announces Two Poster Presentations at the 2018 American Society for Reproductive Medicine (ASRM) Congress & Expo
NEWS PROVIDED BY
INVO Bioscience, Inc.
08:31 ET
https://www.prnewswire.com/news-releases/invo-bioscience-announces-two-poster-presentations-at-the-2018-american-society-for-reproductive-medicine-asrm-congress--expo-300733382.html
Contact PR Newswire
888-776-0942
from 8 AM - 10 PM ET
Chat Online with an Expert
Contact Us
$IVOB
INVO BIOSCIENCE $IVOB SI Increased By 2277.78%
EPS for Neogen (NEOG) Expected At $0.28;
September 7, 2018 - By Mike Johnson
INVO Bioscience, Inc. (OTCMKTS: $IVOB
Analysts expect Neogen Corporation (NASDAQ:NEOG) to report $0.28 EPS on September, 18.They anticipate $0.05 EPS change or 21.74% from last quarter’s $0.23 EPS. NEOG’s profit would be $14.51 million giving it 81.74 P/E if the $0.28 EPS is correct. After having $0.33 EPS previously, Neogen Corporation’s analysts see -15.15% EPS growth. The stock increased 0.94% or $0.85 during the last trading session, reaching $91.55. About 80,733 shares traded. Neogen Corporation (NASDAQ:NEOG) has risen 56.69% since September 7, 2017 and is uptrending. It has outperformed by 44.12% the S&P500. Some Historical NEOG News: 22/03/2018 – NEOGEN 3Q SPLIT ADJ. EPS 32C; 22/03/2018 – Neogen 3Q Rev $95.9M; 06/04/2018 – Jerome Hagedorn Named Neogen VP of Food Safety Ops; 22/03/2018 – NEOGEN CORP NEOG.O : CRAIG-HALLUM RAISES TARGET PRICE TO $65 FROM $63; RATING HOLD; 22/03/2018 – Neogen 3Q EPS 32c; 22/03/2018 – NEOGEN 3Q EPS 32C, EST. 23C; 17/05/2018 – Consolidated Research: 2018 Summary Expectations for TrueCar, Roadrunner Transportation, Eldorado Gold, Neogen, Ashford Hospita; 22/03/2018 NEOGEN 3Q REV. $95.9M, EST. $97.9M; 06/04/2018 – Hagedorn named Neogen VP of food safety operations; 20/04/2018 – DJ Neogen Corporation, Inst Holders, 1Q 2018 (NEOG)
INVO BIOSCIENCE INC (OTCMKTS:IVOB) had an increase of 2277.78% in short interest. IVOB’s SI was 85,600 shares in September as released by FINRA. Its up 2277.78% from 3,600 shares previously. With 539,200 avg volume, 0 days are for INVO BIOSCIENCE INC (OTCMKTS:IVOB)’s short sellers to cover IVOB’s short positions. The SI to INVO BIOSCIENCE INC’s float is 0.1%. The stock decreased 4.14% or $0.02 during the last trading session, reaching $0.41. About shares traded. INVO Bioscience, Inc. (OTCMKTS:IVOB) has 0.00% since September 7, 2017 and is . It has underperformed by 12.57% the S&P500.
Investors sentiment increased to 6.71 in 2018 Q1. Its up 5.22, from 1.49 in 2017Q4. It is positive, as 13 investors sold Neogen Corporation shares while 15 reduced holdings. 27 funds opened positions while 161 raised stakes. 90.94 million shares or 167.86% more from 33.95 million shares in 2017Q4 were reported. Huntington Commercial Bank owns 1,186 shares. Voya Invest Mngmt Ltd Co holds 22,314 shares or 0% of its portfolio. Thrivent Fin For Lutherans, a Minnesota-based fund reported 34,702 shares. Louisiana State Employees Retirement System reported 22,866 shares or 0.07% of all its holdings. Price T Rowe Assocs Md holds 0% or 16,029 shares. New England Private Wealth has invested 0.45% in Neogen Corporation (NASDAQ:NEOG). Raymond James And Assocs owns 4,961 shares for 0% of their portfolio. Ny State Common Retirement Fund accumulated 1.04M shares or 0.09% of the stock. Smithfield owns 46 shares or 0% of their US portfolio. The New York-based Bnp Paribas Arbitrage Sa has invested 0% in Neogen Corporation (NASDAQ:NEOG). Citadel Advisors Ltd Llc holds 206,871 shares or 0.01% of its portfolio. Millennium Mngmt holds 0% or 3,012 shares. Ny State Teachers Retirement Systems holds 52,513 shares or 0.01% of its portfolio. Cambridge Research Advsrs owns 0.02% invested in Neogen Corporation (NASDAQ:NEOG) for 28,354 shares. Creative Planning stated it has 0% of its portfolio in Neogen Corporation (NASDAQ:NEOG).
More recent Neogen Corporation (NASDAQ:NEOG) news were published by: Seekingalpha.com which released: “Neogen acquires genetic services provider for cattle breeding” on September 05, 2018. Also Streetinsider.com published the news titled: “Neogen Corp. (NEOG) to Acquire Livestock Genetic Services” on September 04, 2018. Twst.com‘s news article titled: “Derek Johnston, Portfolio Manager for Conestoga Capital, Owns Neogen (NASDAQ:NEOG), CoStar Group (NASDAQ …” with publication date: August 09, 2018 was also an interesting one.
Neogen Corporation, together with its subsidiaries, develops, makes, and markets various products for food and animal safety worldwide. The company has market cap of $4.75 billion. It operates through two divisions, Food Safety and Animal Safety. It has a 75.66 P/E ratio. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Neogen Corporation (NASDAQ:NEOG) Institutional Positions Chart
https://enbulletin.com/2018/09/07/eps-for-neogen-neog-expected-at-0-28-invo-bioscience-ivob-si-increased-by-2277-78/
$IVOB
https://www.facebook.com/effortlessivfcanada/photos/pcb.2131665480425379/2131665420425385/?type=3
Q2 EPS and revenue should be a good sign..lift off
i traded zyxi last year..now this looks promising..
still holding it.. i have that feeling..
$IVOB: Major NEWS.... 1st INVOCell Pregnancy reported in Alabama
Based on this, $IVOB should alone be $2/sh
Currently at $0.58/sh
**********************************************************
INVO Bioscience and Alabama Fertility Announce First INVOcell Pregnancy in the State of AlabamaFont size: A | A | A
9:01 AM ET 6/12/18 | PR Newswire
RELATED QUOTES
3:40 PM ET 6/11/18
Symbol Last % Chg
IVOB
0.58 0.00%
Real time quote.
BIRMINGHAM, Ala. and MEDFORD, Mass., June 12, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell(TM), today announced that Alabama Fertility, a leading reproductive medicine practice in Birmingham, Alabama, reported the first pregnancy in the State of Alabama utilizing the INVOcell technology.
Beth A. Malizia, MD, a specialist in infertility and reproductive surgery at Alabama Fertility, said, "We are delighted to announce the first INVOcell pregnancy in our clinic and in the state of Alabama. Our patient is 20 weeks pregnant and is doing great. We recently completed a spot on the local evening news -- featuring an interview of our patient and images from her ultrasound - that we expect will air next week. INVOcell is a unique, and cost effective, alternative that may produce desired pregnancies where other treatment options have failed. We believe that INVOcell is a great addition to our scope of services."
Katie Karloff, CEO of INVO Bioscience, commented, "We are pleased that Dr. Beth Malizia and her team have accomplished this important milestone. We greatly appreciate the opportunity to work with them and we look forward to more successful pregnancies in the years to come."
About Alabama Fertility
At Alabama Fertility we are dedicated to helping patients and couples cope with the often complex problems that can affect reproduction. We support patients with reproductive and hormonal difficulties such as infertility and repeated miscarriages, as well as couples needing advanced fertility treatments or reproductive surgery. We offer the most up-to-date methods of diagnosis and treatment including hormone testing, sonography, assisted reproductive techniques and advanced reproductive surgery and microsurgery. At Alabama Fertility, each patient is treated with the understanding and compassion that these complex reproductive problems require.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology ("ART"). The INVOcell is the first Intravaginal Culture ("IVC") system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization ("IVF") and Intrauterine Insemination ("IUI"). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will, " and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504
kkarloff@invobio.com
View original content with multimedia:http://www.prnewswire.com/news-releases/invo-bioscience-and-alabama-fertility-announce-first-invocell-pregnancy-in-the-state-of-alabama-300664756.html
SOURCE INVO Bioscience, Inc.
/Web site: https://invobioscience.com
> Dow Jones Newswires
June 12, 2018 09:01 ET (13:01 GMT)
everyone is holding it strong..lets see in few weeks any news..
Waiting
Couple has baby using INVOcell, an alternative to IVF
http://wtkr.com/2018/06/03/local-couple-has-baby-using-invocell-an-alternative-to-ivf/
Dr. Kevin recently met with Dr. Mehmet Oz in China to discuss the challenges of global access to fertility care.
https://www.facebook.com/effortlessivfus/photos/a.2005587739658831.1073741827.1741272319423709/2024540324430239/?type=3&theater
more today.. and waiting on story..
buying these here and there...waiting for q1..story
More great news from China:
http://www.xinhuanet.com/english/2018-05/08/c_137162370.htm
This could represent more sales than the US. They are partnering with Chinese medical groups and pioneering western medicine integration with Chinese. This will lend much credibility and acceptance of our technology!
INVO goes to China
https://www.facebook.com/search/top/?q=invobioscience
Lots of good media coverage lately. See Yahoo board: https://finance.yahoo.com/quote/IVOB/community?p=IVOB
The Fertility Institute of New Orleans has accomplished over 17,000 pregnancies, and has four locations from Baton Rouge to New Orleans.
noticed but no cash to buy anything. :(
To the Moon ???????????? you better get on quick while you can ??????
Has been lower...
so the bottom was in around 10-11 cents
IVOB going global!
https://finance.yahoo.com/news/invo-bioscience-progresses-developing-market-113000239.html
There are 10 in-vitro fertilization (IVF) centers in Hong Kong performing approximately 11,000 treatment cycles annually. It is estimated that there are approximately 150,000 infertile couples in the Hong Kong area. With just over 7 percent of fertility cases being treated, Hong Kong and Macao with over 8 million people represent a large market opportunity that can benefit from the effective and cost-efficient treatment that utilizing the INVOcell offers.
INVO Bioscience has established an agreement with a major Hong Kong-based medical device distributor to serve this large and growing market in the Hong Kong area. INVO Bioscience has coordinated training sessions on the INVO Procedure by leading North American physicians and embryologists in the Hong Kong market.Approximately 70 fertility physicians and embryologists have recently been trained; 10 of the doctors just last month.
http://www.cbc.ca/news/canada/calgary/calgary-effortless-ivf-clinic-fertility-1.4109659
Read the last two paragraphs...
Like it!
Another signing!
The New Hope Center for Reproductive Medicine Adds INVOcell to its Lineup of Reproductive Services
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity.
NEWS PROVIDED BY
INVO Bioscience, Inc.
09:01 ET
SHARE THIS ARTICLE
VIRGINIA BEACH, Va. and MEDFORD, Mass., Feb. 9, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced an additional leading East Coast-based reproductive services provider has added INVOcell to its list of reproductive treatments.
INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman's body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit while reducing the risk of wrong embryo transfer. Utilizing a mild stimulation protocol, it decreases the number of oocytes required, which may reduce the risk of severe ovarian hyperstimulation (OHSS), reduce the risk of multiple births, and/or reduce the need for embryo cryopreservation and storage. As a lower cost option to traditional IVF, INVOcell expands access to patients who may otherwise cannot afford the traditional method or would prefer for a more natural, cultural, or religious appropriate choice.
The New Hope Center for Reproductive Medicine, located in Virginia Beach, Virginia, is now offering INVOcell fertility treatment to their broad palette of fertility services. For many couples dealing with infertility, the cost of in-vitro fertilization ("IVF") can be a barrier to getting the baby they desire. Others are faced with a religious or cultural dilemma when needing to decide what to do with excess embryos. For couples such as these, a new, more natural method of treatment offered at The New Hope Center – INVOcellTM could be the answer. The procedure is more cost effective due to the elimination of certain IVF Lab procedures, and typically produces less embryos due to the minimal stimulation/medication regimen used, while still offering a comprehensive treatment option for these couples.
Dr. Robin Poe-Zeigler, founder of The New Hope Center, said, "We are humbled by the thousands of patients who have entrusted us with their care, while assisting them with their fertility journey on the way to parenthood. We are dedicated to providing the highest quality infertility testing and treatment, using cutting edge techniques and technology, including INVOcell, to achieve the best possible outcome for each and every patient. We believe that INVOcell represents a unique option to many couples that could not otherwise undergo fertility treatments in a fiscally responsible manner."
Katie Karloff, Chair and Chief Executive Officer of INVO Bioscience, commented, "Dr. Robin Poe-Zeigler and The New Hope Center provide great hope and compassion to couples in the mid-Atlantic region that are challenged to achieve the pregnancy they so desire. Throughout the years, Dr. Robin and her team have made pregnancies possible that have brought thousands of babies into the world. We are pleased that The New Hope Center has included our INVOcell treatment as a unique option that can help fulfill the dreams of building families."
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/
Looks like they have a working product!
I am losing my backside here.... what the heck is going on.... I truly. Don’t understand being down now over 30% Is there light at theend of the tunnel.... way too big of a drop IMHO
FeedBack Please
Pretty Quiet Thread here.... how about some more insight and opinions on this company?
Staying the course... I am all in.... Fingers Crossed...
That's a hard call. I am holding, but if you are not all in, I think I would stay on the sidelines until I see a reversal. The chart looks abysmal at this point! Of course, they could announce financing any day, and that and plans to open clinics could spike it up before you have a chance to get in.
So... What in your opinion is the short term and long term outlook of investing with INVO. Trying to figure out if I should be investing more heavily here... Still limited information and updates that I can find... Thanks in Advance...
Rob once told me that they weren't social media types.
The rest of the world is, though. They need to get on the ball!
Send them an email.
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1112
|
Created
|
04/05/09
|
Type
|
Free
|
Moderators |
INVO Bioscience Product InformationINVO Bioscience's INVOcell will revolutionize the treatment of infertility. The INVOcell, pictured below, replaces the IVF laboratory and allows conception to take place naturally inside the woman's body. INVO Bioscience's INVOcell device and the INVO process will be much less expensive than traditional IVF and is comparable in pregnancy rate. Also, the INVO procedure is simple so it will be available in physician's offices. The INVOcell Device The INVOcell device and procedure were developed by Dr. Claude Ranoux. Over 800 clinical cases using prototype devices have been published in the medical literature. The INVOcell is a precisely designed and manufactured device. The INVOcell is manufactured in the U.S. by a company that is ISO-13485 certified. INVO Bioscience has 5 current patents on the INVOcell device and procedure.“This technology represents an exciting and important new treatment option for infertility.” Dr. Leo Bonaventura, INVOcell Clinical Investigator and member of INVO Bioscience's Board of Advisors, |
Chat forum for woman who were in the Trials! Lots of great feedback! |
11/03/2015 - Pr Newswire | |
The Economist-Oct 25, 2014 IT IS not quite do-it-yourself IVF, but it is close. An INVOcell, brainchild of Claude Ranoux of INVO Bioscience, in Medford, Massachusetts, is a device that allows ... | |
The 'champagne cork' mini incubator that could halve cost of IVFDaily Mail-Oct 22, 2014 In a pilot study, women treated using the INVOcell device were just as likely to ... INVO Bioscience hopes to have the device on sale in the US by the end of this ... | |
Mini 'body incubator' may halve cost of IVFIndependent Online-Nov 4, 2014 In a pilot study of 33 infertile women, those treated using the INVOcell ... INVO Bioscience hopes to have the device on sale in the US by the end of this year. | |
The INVO procedure has been published in The Scientific World Journal! INVO Procedure: Minimally Invasive IVF as an Alternative Treatment Option for Infertile Couples Click Here for Active Stock Bid Information IR@INVOBio.com |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |